Skip to content

David Shen



Shen David
David Shen



David heads the IP practice in China. Native Chinese and an experienced U.S. patent lawyer, David has extensive experience in representing multinational companies in the protection, licensing, and enforcement of IP rights in China. David’s IP experience includes significant patent, trademark and branding experience with a particular focus on the life sciences sector. With a strong technical background, a deep understanding of the Chinese legal system, and a global view on IP protection, David offers unparalleled legal support to companies doing business in China. David was formerly the China General Counsel for a leading global multinational pharmaceutical company. 

“David provides technically savvy counsel of the utmost value, enforcing life sciences rights globally and negotiating complex licensing agreements.” IAM 1000, 2018 


News & insights

Publications: 13 NOVEMBER 2019

Regulation of technology import: China

Despite being both lawful and commonplace to choose foreign governing law and foreign forum in a technology import contract entered into between a foreign transferor and a Chinese transferee, it is impracticable for the foreign party to the contract to avoid the Chinese court when it seeks to enforce against the Chinese counterparty. As the Chinese court is virtually inevitable where enforcement is sought against the Chinese transferee, so is the application of mandatory Chinese law.

Read more

Publications: 02 SEPTEMBER 2019

China: amendment to Drug Administration Law

On August 26, 2019, the China’s National People’s Congress passed the amended Drug Administration Law (the Amended DAL) which will take effect on December 1.

Read more

Publications: 20 MARCH 2019

China's new Foreign Investment Law - a new era for foreign investment in China?

​The Foreign Investment Law of the People’s Republic of China (FIL) was approved and passed by the National People’s Congress (NPC) on 15 March 2019. In its current form, the FIL will become effective at the beginning of 2020, at which time it will replace the set of Chinese laws commonly known as the “Three Enterprise Laws” that has been the seminal legislation governing foreign investment in China since the early 1980s. 

Read more

Publications: 12 DECEMBER 2018

China Announces Pilot Scheme for Tendering with Minimum Procurement Quantities

On 15 November 2018 the Joint Procurement Office (the JPO) published its Paper on Centralized Drug Procurement in “4+7” Cities (the Paper), which launched the national pilot scheme for tendering with minimum procurement quantities. The pilot scheme will be carried out in 11 cities: Beijing, Tianjin, Shanghai, Chongqing, Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xian, which represent the lion’s share of the Chinese drug market.

Read more



Allen & Overy LLP Shanghai Representative Office (UK)
15F, Phase II, Shanghai IFC, 8 Century Avenue, Pudong

View office →



Admitted to the Bar, State of Pennsylvania, USA 2006

Admitted to the Bar, State of New Jersey, USA 2006

Registered to practice before the United States Patent and Trademark Office 2006


Ph.D. Chemistry, Cornell University

J.D. Temple University